Zhang, Jinfang
Bu, Xia
Wang, Haizhen
Zhu, Yasheng
Geng, Yan
Nihira, Naoe Taira
Tan, Yuyong
Ci, Yanpeng
Wu, Fei
Dai, Xiangpeng
Guo, Jianping
Huang, Yu-Han
Fan, Caoqi
Ren, Shancheng
Sun, Yinghao
Freeman, Gordon J.
Sicinski, Piotr
Wei, Wenyi
Article History
Received: 12 July 2017
Accepted: 8 November 2017
First Online: 16 November 2017
Competing interests
: G.J.F. has patents and pending royalties on the PD-1 pathway from Roche, Merck, Bristol-Myers-Squibb, EMD-Serono, Boehringer-Ingelheim, AstraZeneca, DAKO and Novartis. G.J.F. has served on advisory boards for CoStim, Novartis, Roche, Eli Lilly, Bristol-Myers-Squibb, Seattle Genetics, Bethyl Laboratories, Xios, and Quiet. P.S. is a consultant and a recipient of a research grant from Novartis. No potential conflicts of interests were disclosed by other authors.